173 related articles for article (PubMed ID: 20647025)
1. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1361-2. PubMed ID: 20647025
[No Abstract] [Full Text] [Related]
2. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
Paulzen M; Gründer G
Int J Neuropsychopharmacol; 2007 Feb; 10(1):149-51. PubMed ID: 16942633
[No Abstract] [Full Text] [Related]
3. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
4. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
J Clin Psychopharmacol; 2011 Jun; 31(3):400-1; author reply 401. PubMed ID: 21532377
[No Abstract] [Full Text] [Related]
5. Reversal of symptomatic hyperprolactinemia by aripiprazole.
Wahl R; Ostroff R
Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
[No Abstract] [Full Text] [Related]
6. Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient.
Chen CH; Huang MC; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):893-4. PubMed ID: 18082301
[No Abstract] [Full Text] [Related]
7. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
Saitis M; Papazisis G; Katsigiannopoulos K; Kouvelas D
Psychiatry Clin Neurosci; 2008 Oct; 62(5):624. PubMed ID: 18950388
[No Abstract] [Full Text] [Related]
8. Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient.
Chen ST; Hsiao YL
J Clin Psychopharmacol; 2010 Feb; 30(1):78-80. PubMed ID: 20075655
[No Abstract] [Full Text] [Related]
9. Aripiprazole treatment of risperidone-induced hyperprolactinemia.
Chen JX; Su YA; Wang SL; Bian QT; Liu YH; Wang N; Yang FD; Haile C; Kosten TR; Zhang XY
J Clin Psychiatry; 2009 Jul; 70(7):1058-9. PubMed ID: 19653986
[No Abstract] [Full Text] [Related]
10. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Lee BH; Kim YK; Park SH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole reverses paliperidone-induced hyperprolactinemia.
Basterreche N; Zumárraga M; Arrue A; Olivas O; Dávila W
Actas Esp Psiquiatr; 2012; 40(5):290-2. PubMed ID: 23076612
[TBL] [Abstract][Full Text] [Related]
12. Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
Lian J; Huang XF; Pai N; Deng C
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1157-8; author reply 1159. PubMed ID: 20381569
[No Abstract] [Full Text] [Related]
13. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
14. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
16. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
17. Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.
Rocha FL; Hara C; Ramos MG
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1153-4. PubMed ID: 20547197
[No Abstract] [Full Text] [Related]
18. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Lin SK; Chen CK
J Clin Psychiatry; 2006 Aug; 67(8):1307. PubMed ID: 16965214
[No Abstract] [Full Text] [Related]
19. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
Hoffer ZS; Roth RL; Mathews M
Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
[TBL] [Abstract][Full Text] [Related]
20. Hyperprolactinemia with aripiprazole: understanding the paradox.
Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
